Premarket Biotech Digest – $ISR launches pilot study, $BMY flunks trial, $AZN terminates project

Bristol-Myers Squibb ($BMY) announced negative results for its leukemia drug study. The company is collaborating with Innate Pharmaceuticals for this project. Lirilumab failed to beat a placebo in improving patients' leukemia-free survival. This mid-stage trial showed there was no statistically significant difference identified between [...]

By |February 6th, 2017|Digest|0 Comments

Premarket Biotech Digest – $IPCI receives FDA nod, $GEN inks new deal, $AMGN receives buy rating

Benitec Biopharma ($BNTC) announced that it has significant milestone with regard to its ddRNAi technology to treat ocular diseases, particularly with identifying novel viral vectors. The new development will enable the delivery of the gene therapy to the retina via intravitreal injection. Current ocular [...]

By |February 3rd, 2017|Digest|0 Comments

Premarket Biotech Digest – $LCI reports Q2 earnings, $SNY receives FDA approval, $VCL reports implants

Sarepta Therapeutics Inc. ($SRPT) stock stumbled as the company grappled with the consequences of failing reimbursement issues related to Exondys 51. There had been several analyst reports circulating that the reimbursement situation related to this Duchenne muscular dystrophy (DMD) med is dire. The company [...]

By |February 2nd, 2017|Digest|0 Comments

Premarket Biotech Digest – $PTN closes deal, $MDWD reports study results, $TENX announces trial failure

Mediwound Ltd ($MDWD) stock jumped over 9% in Tuesday trading session as the company announced final positive results from the Company’s second Phase 2 clinical trial evaluating EscharEx® for debridement of dead or damaged tissue in chronic and other hard-to-heal wounds. It also reported [...]

By |February 1st, 2017|Digest|0 Comments

Premarket Biotech Digest – $TEVA loses patent, $LLY reports quarterly results, $RIGL announces trial results

Premarket Biotech Digest – $TEVA loses patent, $LLY reports quarterly results, $RIGL announces trial results $Digest, $TEVA,$LLY,$RIGL Mylan NV ($MYL) announced that it is being investigating by the US antitrust authorities for its EpiPen emergency allergy treatment. The company was earlier asked for information [...]

By |January 31st, 2017|Digest|0 Comments

Premarket Biotech Digest – $RNN provides update, $QURE receives FDA nod, $MNK completes divestment

Calithera Biosciences ($CALA) stock jumped in the premarket session as the company announced its new global collaboration and license agreement with Incyte Corporation. The agreement deals with research, development and commercialization of Calithera’s first-in-class, small molecule arginase inhibitor CB-1158 in hematology and oncology. The [...]

By |January 30th, 2017|Digest|0 Comments

Premarket Biotech Digest – $OPK launches new study, $JNJ receives FDA clearance, $BIIB announces results

Cynosure Inc. ($CYNO) reported in a regulatory filing that it has entered into an agreement to settle a class action lawsuit filed by ARcare, Inc. The lawsuit was filed in July 2016 and had accused the firm of violating the federal Telephone Consumer Protection [...]

By |January 27th, 2017|Digest|0 Comments

Premarket Biotech Digest – $GILD to report results, $ELGX gets CE mark, $ALDX to start trial

McKesson ($MCK) announced its intent to acquire privately-held healthcare IT company CoverMyMeds for nearly $1.1 billion. The company said the deal will strengthen its technology offerings to pharmaceutical manufacturers, clinicians and payers. The company also reported encouraging financial results for its third quarter. The [...]

By |January 26th, 2017|Digest|0 Comments

Premarket Biotech Digest – $JNJ provides forecast, $XON announces acquisition, $RHHBY gets FDA nod

Flex Pharma ($FLKS) announced that it plans to reorganize its clinical activities. As the result of this exercise, the firm will de-prioritize its clinical development activities in nocturnal leg cramps in favor of severe neurological diseases, specifically amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) [...]

By |January 25th, 2017|Digest|0 Comments

Premarket Biotech Digest – $ENDP announces settlement, $MCUR completes merger, $RMD reports Q2 results

Aetna Inc. ($AET) has stumbled onto a new issue as its Humana acquisition has been blocked by the US regulators. The deal is worth nearly $34 billion. The U.S. Justice Department filed a lawsuit last July to block Aetna's acquisition of Humana, citing that [...]

By |January 24th, 2017|Digest|0 Comments

Premarket Biotech Digest – $INFI announces +ve trial results, $AQB completes listing, $BVX inks deal

Merck ($MRK) has agreed to settle its Keytruda patent case with Bristol-Myers Squibb ($BMY). Another firm Ono Pharmaceuticals Company Ltd. is also involved in the case. Both these companies had claimed that Merck’s Keytruda infringed on their patents related to the use of PD-1 [...]

By |January 23rd, 2017|Digest|0 Comments

Premarket Biotech Digest –$VRX moves up, $SGYP gets FDA approval, $OFIX to pay penalty

Cytori Therapeutics ($CYTX) announced the acquisition of certain assets from Azaya Therapeutics, which is a privately held firm. Under the terms of the deal, Cytori will issue $2 million in Cytori common stock up front. It will also assume nearly $2 million of Azaya’s [...]

By |January 20th, 2017|Digest|0 Comments

Premarket Biotech Digest – $APRI receives approval, $AGN to pay penalty, $TEVA receives FDA nod

Abbott Laboratories ($ABT) announced that it has launched its Proclaim DRG Neurostimulation System in Europe. The system is designed to deliver dorsal root ganglion stimulation to patients with chronic neuropathic pain. The system is magnetic resonance conditional. It is also recharge free and is [...]

By |January 19th, 2017|Digest|0 Comments

Premarket Biotech Digest – $ARRY retains momentum, $MCK to pay penalty, $BIIB announces collaboration

Celsion Corporation ($CLSN) stock climbed to its intraday high of $0.62 in the Tuesday trading session. The stock eventually closed at $0.510, up 30.77%. The company announced continued data from the fourth cohort of patients in its Phase Ib dose escalating clinical trial (the [...]

By |January 18th, 2017|Digest|0 Comments

Premarket Biotech Digest – $CYTR continues upmove, $FWP signs settlement, $UNH reports results

Forward Pharma A/S ($FWP) surged in the premarket session as it emerged that it has signed a Settlement and License Agreement with Biogen ($BIIB). Both the companies were engaged in a dispute over a patent covering methods of treating multiple sclerosis (MS) with 480 [...]

By |January 17th, 2017|Digest|0 Comments

Premarket Biotech Digest – My New Swing Trading Group Accepting Members, $SGYP surges, $HLF reprieved, $AXON rating

== Make Money Swing Trading - Join My New Trading Group - Email drkkde@gmail.com Now == == Synergy Pharmaceuticals Inc. ($SGYP) stock continues its strong upward movement in the new year. The company stock has gained 67% in the past one year while its [...]

By |January 16th, 2017|Digest|0 Comments

Premarket Biotech Digest – $MSTX acquires Savara, $LLY receives positive ruling, $SHPG settles case

Mast Therapeutics Inc. ($MSTX) stock gained over 60% in the past 5 days as the company announced its merger with specialty Pharmaceuticals company Savara Inc. Under the terms of the agreement, stockholders of Savara would become the majority owners of Mast, and the operations [...]

By |January 13th, 2017|Digest|0 Comments

Premarket Biotech Digest – $BIOC signs new contract, $ISRG receives neutral rating, $BSX to launch new product

Histogenics ($HSGX) stock jumped over 54% in its pre-market session. The stock responded to the news of positive data from Phase 1 & 2 studies assessing lead product candidate NeoCart for the repair of articular cartilage injuries in the knee. The tests were conducted [...]

By |January 12th, 2017|Digest|0 Comments

Premarket Biotech Digest – $ETRM soars, $RHHBY announces acquisition, $RDY launches new products

EnteroMedics Inc. ($ETRM) stock showed strong moves in its Tuesday trading session as it jumped to its intraday high of $30.41. The stock eventually closed at $27.70, up 56.5% from its previous close. The company recently announced the development of its new treatment called [...]

By |January 11th, 2017|Digest|0 Comments

Premarket Biotech Digest – $ILMN launches DNA sequencer, $GALE receives subpoena, $INCY gets buy rating

Illumina ($ILMN) announced the launch of a new DNA sequencer with new architecture. The new sent the stock over 11% up in the pre-market session. The company said that the new architecture may lower the costs of decoding human genome considerably. Illumina is of [...]

By |January 10th, 2017|Digest|0 Comments
s2Member®